ANZCTR search results

We believe that the addition of either 5mh of droperidol or 5mg olanzapine immediately prior to sedation with midazolam will result in safe and more effective sedation

This study is assessing two different chemotherapy treatments – Brivanib and Cetuximab versus Cetuximab and standard treatment – in treating people with metastatic (secondary distant) colorectal (K-Ras Wild Type) cancer who have previously been treated with combination chemotherapy. Who is it for? You can join this study if you have completed the standard chemotherapy for metastatic colorectal cancer. Trial details Participants will be randomly divided into two groups. One group will receive a combination of a compound known as oral Brivanib in combination with Cetuximab; the other will receive standard treatment in combination with Cetuximab. The trial will eventually assess if there is a difference in overall survival between the two groups. Brivanib blocks a compound known as ‘vascular endothelial growth factor receptor 2’ (VEGFR2) and this may result in the inhibition of tumour blood vessel growth. Cetuximab blocks another factor called the ‘epidermal growth factor receptor’ (EGFR) and so inhibits cell growth. If your cancer has increased in size on standard treatment for metastatic colorectal cancer (which might included 5-fluorouracil, oxaliplatin and irinotecan), your treatment options are limited. Cetuximab works in this setting but it is not part of the standard treatment. This purpose of this trial is to test if the combination of Brivanib and Cetuximab versus Cetuximab alone improve survival if the treatment you have been receiving has not worked.

Assessment of various tafenoquine dose regimens to determine the most effective dose for post exposure prophylaxis of P.vivax malaria in the Southwest Pacific

We aim to investigate and compare the effects of raloxifene and tamoxifen (two most commonly used SERMs) in healthy men and women on the growth hormone system and metabolism.

Introduction Feeling sick in labour is a common problem which can cause additional distress. These symptoms probably occur due to pain, anxiety and drug side effects. We are interested in studying the potential effect of using acupressure wrist bands to stop nausea and vomiting in this setting. This is a non-drug remedy, related to acupuncture, involving applying pressure to a point near the wrist. It has been shown to be successful in combating sickness in other situations such as post-operative nausea and vomiting, and morning sickness. Aims/Objectives/Hypotheses The study aims to look at the rates of sickness in women wearing acupressure wristbands (PressureRightTM) compared to baseline levels and those wearing dummy (placebo) bands. Study Population We will be studying women who are in good health, aged18 years or older, in full term labour admitted to the labour ward and who consent to taking part in our trial. They will receive information about the project and they will be able to withdraw from the study at any time. We will not be looking at women who are morbidly obese, known to be intravenous drug users, have an allergy to tapes, have an abnormal or dead baby, do not speak English, and/or are using acupressure techniques or medications to treat nausea already. Methods Women who have agreed and signed a written consent will be randomly assigned to one of the two groups, treatment group with the bands applied correctly and placebo group with dummy (placebo) bands. Both types of bands will be covered. We will collect baseline information such as age, weight, height, pregnancy details, smoking status, history of motion sickness, progress of labour, use of medications, presence of initial nausea and pain. Further information will be collected during the labour by way of a simple form (with midwife help). This will include sickness and pain severity. The rest of the required information including the use of any medications during labour, use of an epidural, basic observations such as blood pressure, and the level of satisfaction with their care will be collected post delivery. Ethical Issues There are no significant ethical issues in the performance of this study.

Laboratory studies indicate that CYT997 is able to potently inhibit myeloma cells from patients with this condition. Given these favourable "test tube" findings, Cytopia has decided to investigate whether CYT997, when given to patients with multiple myeloma, can improve their condition and extend survival from the disease. The effect of CYT997 in patients will be determined from analysis of blood plasma and bone marrow samples and comparison to accepted clinical standards for response in multiple myeloma.

This project will examine three approaches to the management of chronic obstructive pulmonary disease. It will evaluate whether any of the approaches are superior in terms of better outcomes and also which one is most economical relative to its benefits. The three approaches are a self-management approach, a structured respiratory rehabilitation program and standard general medical practice management.

The aim is to promote testing for chlamydia among at-risk 16 – 25 year old Australians. A website about chlamydia will be developed in consultation with young people, and linked to an existing, evaluated health promotion website. Eligible visitors to the chlamydia website will be invited to participate in the study. 1,000 participants will be randomly allocated into one of two groups. The intervention group will be offered confidential email interaction with a nurse or doctor to discuss their needs and barriers surrounding testing for chlamydia. The control group will receive an automated email reply directing them back to the website for information. Both groups will complete a de-identified online questionnaire at baseline and 6 months. The main outcome measure will be whether chlamydia testing took place.

The purpose of the study is to test if an experimental topical drug is effective in reducing under-arm perspiration in people who have excessive under-arm perspiration

This study will evaluate the safety (i.e. incidence and type of adverse events) and efficacy (i.e. as measured by complete clearance) of AS101 administered twice daily topically over a treatment period of up to 16 weeks, or until complete clearance of external genital warts in the treatment area.